A 22-week Randomized, Cross-over Study Comparing the Effects of Quinapril and Quinapril Plus Alpha-lipoic Acid (ALA) on Patients With Diabetes Mellitus and Hypertension (QUALITY)

NCT00795262 NA COMPLETED

We will evaluate the combination of quinapril and alpha lipoic acid in patients with diabetes mellitus and hypertension. We will determine whether the combination of quinapril and lipoic acid as compared to quinapril and placebo provides benefit on systemic blood pressure and proteinuria.

Details

Lead sponsor	InVasc Therapeutics, Inc.
Phase	NA
Status	COMPLETED
Enrolment	23
Start date	2008-07
Completion	2009-07

Conditions

• Diabetes
• Hypertension

Interventions

• Quinapril (Accupril) plus Alpha Lipoic Acid
• accupril, placebo
• accupril, alpha lipoic acid

Primary outcomes

• Comparison of relative change of systolic BP/diastolic BP and urinary albumin excretion from baseline in diabetic patients treated with quinapril plus lipoic acid versus quinapril and placebo. — The total study period is 22 weeks i.e. the initial prescreening visit followed 1 week later by the baseline study visit, 8 weeks of treatment (Treatment A or B), 4 weeks washout, 8 weeks of treatment (Treatment A or B).

Countries

United States